Ny krystallinsk form III av agomelatin, fremgangsmåte for dens fremstilling og farmasøytiske sammensetninger inneholdende den

Krystallinsk form III av forbindelsen med formel (l): karakterisert ved dens pulverrøntgendiffraksjonsdiagram. Medikamenter. Crystalline form III of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide is new. The compound is confirmed by powder X-ray diffraction pattern as given in the specif...

Full description

Saved in:
Bibliographic Details
Main Authors SOUVIE JEAN-CLAUDE, COQUEREL GÉRARD, LINOL JULIE
Format Patent
LanguageNorwegian
Published 21.12.2015
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Krystallinsk form III av forbindelsen med formel (l): karakterisert ved dens pulverrøntgendiffraksjonsdiagram. Medikamenter. Crystalline form III of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide is new. The compound is confirmed by powder X-ray diffraction pattern as given in the specification. An independent claim is included for preparation of the crystalline form III of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide involves: heating agomelatine at 110[deg]C until fully melted, and then slowly cooled until recrystallization occurs. ACTIVITY : Hypnotic; Tranquilizer; Antidepressant; Gastrointestinal-Gen; CNS-Gen; Cardiovascular-Gen.; Neuroleptic; Muscular-Gen.; Immunomodulator; Eating-Disorder-Gen.; Anorectic; Anticonvulsant; Antidiabetic; Antiparkinsonian; Nootropic; Neuroprotective; Dermatological; Antimigraine; Cerebroprotective; Endocrine-Gen.; Cytostatic; Analgesic; Contraceptive. MECHANISM OF ACTION : Melatoninergic system receptor agonist; 5-HT(hydroxytryptamine)-2C receptor antagonist. No biological data given.
Bibliography:Application Number: NO20060003516